Due to the rapid, vast, and emerging global spread of the Coronavirus Disease 2019
(COVID-19) pandemic, many drugs were quickly repurposed in a desperate attempt to …

SARS-CoV-2, the causative agent of COVID-19, predominantly affects the respiratory tract.
As a consequence, it seems intuitive to develop antiviral agents capable of targeting the …

Pharmacokinetic limitations associated with oral ivermectin may limit its success as a
potential COVID-19 treatment based on in vitro experiments which demonstrate antiviral …

Ivermectin was first approved for human use as an endectocide in the 1980s. It remains one
of the most important global health medicines in history and has recently been shown to …

Objectives Therapy failure caused by complex population-drug-drug (PDDI) interactions
including CYP3A4 can be predicted using mechanistic physiologically-based …

More than two years have passed since the viral outbreak that led to the novel infectious
respiratory disease COVID-19, caused by the SARS-CoV-2 coronavirus. Since then, the …

Ivermectin, an FDA-approved antiparasitic drug, has been reported to have in vitro activity
against SARS-CoV-2. Increased off-label use of ivermectin for COVID-19 has been reported …

Since it was proposed as a potential host-directed antiviral agent for SARS-CoV-2, the
antiparasitic drug ivermectin has been investigated thoroughly in clinical trials, which have …

The emergence of multidrug-resistant strains requires the urgent discovery of new
antibacterial drugs. In this context, an antibacterial screening of a subset of anthelmintic …

Recent reports have suggested that the susceptibility of cells to SARS-CoV-2 infection can
be influenced by various proteins that potentially act as receptors for the virus. To investigate …